Targeting PSD95-nNOS interaction by Tat-N-dimer peptide during status epilepticus is neuroprotective in MAM-pilocarpine rat model

[1]  Massimo Rizzi,et al.  Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy , 2019, Brain : a journal of neurology.

[2]  A. Kanthasamy,et al.  Status Epilepticus: Behavioral and Electroencephalography Seizure Correlates in Kainate Experimental Models , 2018, Front. Neurol..

[3]  A. Hohmann,et al.  Small molecule inhibitors of PSD95–nNOS protein–protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats , 2017, Neuroscience.

[4]  M. Lauritzen,et al.  PSD-95 uncoupling from NMDA receptors by Tat-N-dimer ameliorates neuronal depolarization in cortical spreading depression , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Mushfiquddin Khan,et al.  Targeting the nNOS/peroxynitrite/calpain system to confer neuroprotection and aid functional recovery in a mouse model of TBI , 2016, Brain Research.

[6]  G. Battaglia,et al.  Continuous neurodegeneration and death pathway activation in neurons and glia in an experimental model of severe chronic epilepsy , 2015, Neurobiology of Disease.

[7]  Simon Shorvon,et al.  A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus , 2015, Epilepsia.

[8]  P. Schwartzkroin,et al.  Nodule excitability in an animal model of periventricular nodular heterotopia: c‐fos activation in organotypic hippocampal slices , 2015, Epilepsia.

[9]  T. Thippeswamy,et al.  Seizure-Induced Oxidative Stress in Temporal Lobe Epilepsy , 2015, BioMed research international.

[10]  R. Silverman,et al.  Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain. , 2014, Chemical Society reviews.

[11]  G. Battaglia,et al.  Progressive Brain Damage, Synaptic Reorganization and NMDA Activation in a Model of Epileptogenic Cortical Dysplasia , 2014, PloS one.

[12]  E. Aronica,et al.  Cell injury and Premature Neurodegeneration in Focal Malformations of Cortical Development , 2014, Brain pathology.

[13]  C. Marras,et al.  Long-duration epilepsy affects cell morphology and glutamatergic synapses in type IIB focal cortical dysplasia , 2013, Acta Neuropathologica.

[14]  D. Naylor,et al.  Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus , 2013, Neurobiology of Disease.

[15]  M. Doucet,et al.  Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice , 2013, Neuropsychopharmacology.

[16]  G. Sills,et al.  N w‐Propyl‐l‐arginine (L‐NPA) reduces status epilepticus and early epileptogenic events in a mouse model of epilepsy: behavioural, EEG and immunohistochemical analyses , 2012, The European journal of neuroscience.

[17]  Michael D Hill,et al.  Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial , 2012, The Lancet Neurology.

[18]  A. Jeromin,et al.  Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases , 2012, Current Translational Geriatrics and Experimental Gerontology Reports.

[19]  Patrik Lundström,et al.  A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage , 2012, Proceedings of the National Academy of Sciences.

[20]  Annamaria Vezzani,et al.  Status epilepticus-induced pathologic plasticity in a rat model of focal cortical dysplasia. , 2011, Brain : a journal of neurology.

[21]  Jackson Streeter,et al.  Blood-based diagnostics of traumatic brain injuries , 2011, Expert review of molecular diagnostics.

[22]  W. Lu,et al.  Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95 , 2010, Nature Medicine.

[23]  A. Gabrielli,et al.  αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. , 2010, Journal of neurotrauma.

[24]  Doo-Kwun Kim.  Increased Seizure Susceptibility and Up-regulation of nNOS Expression in Hippocampus Following Recurrent Early-life Seizures in Rats , 2010, Journal of Korean medical science.

[25]  A. Hao,et al.  Oxidative stress mediates hippocampal neuron death in rats after lithium–pilocarpine-induced status epilepticus , 2010, Seizure.

[26]  J. Rosenow,et al.  Cellular injury and neuroinflammation in children with chronic intractable epilepsy , 2009, Journal of Neuroinflammation.

[27]  J. González-Martínez,et al.  Neuronal nitric oxide synthase expression in resected epileptic dysplastic neocortex. , 2009, Journal of neurosurgery.

[28]  J. Gurd,et al.  Neuroprotection After Status Epilepticus by Targeting Protein Interactions With Postsynaptic Density Protein 95 , 2009, Journal of neuropathology and experimental neurology.

[29]  Andrew M. White,et al.  Development of Spontaneous Recurrent Seizures after Kainate-Induced Status Epilepticus , 2009, The Journal of Neuroscience.

[30]  A. Vercelli,et al.  Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis , 2008, Neurobiology of Disease.

[31]  B. Bahr,et al.  Calpain activation is involved in early caspase‐independent neurodegeneration in the hippocampus following status epilepticus , 2008, Journal of neurochemistry.

[32]  A. Sbarbati,et al.  Pilocarpine-Induced Status Epilepticus in Rats Involves Ischemic and Excitotoxic Mechanisms , 2007, PloS one.

[33]  Rajeev Agarwal,et al.  Activity‐dependent Gene Expression Correlates with Interictal Spiking in Human Neocortical Epilepsy , 2007, Epilepsia.

[34]  E. Hall,et al.  Temporal relationship of peroxynitrite-induced oxidative damage, calpain-mediated cytoskeletal degradation and neurodegeneration after traumatic brain injury , 2007, Experimental Neurology.

[35]  L. Tassi,et al.  NMDA Receptor Composition Differs Among Anatomically Diverse Malformations of Cortical Development , 2006, Journal of neuropathology and experimental neurology.

[36]  P. Neumann,et al.  Peroxynitrite mediates TNF-α-induced endothelial barrier dysfunction and nitration of actin , 2006 .

[37]  J. González-Martínez,et al.  The NMDA receptor NR2B subunit contributes to epileptogenesis in human cortical dysplasia , 2005, Brain Research.

[38]  R. Astur,et al.  Selective Cognitive Impairments Associated with NMDA Receptor Blockade in Humans , 2005, Neuropsychopharmacology.

[39]  I. Najm,et al.  Increased Numbers of Coassembled PSD‐95 to NMDA‐receptor Subunits NR2B and NR1 in Human Epileptic Cortical Dysplasia , 2004, Epilepsia.

[40]  M. Tymianski,et al.  Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors. , 2003, Biochemical pharmacology.

[41]  Ramesh C. Gupta,et al.  Prevention of kainic acid seizures-induced changes in levels of nitric oxide and high-energy phosphates by 7-nitroindazole in rat brain regions , 2003, Brain Research.

[42]  Yitao Liu,et al.  Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions , 2002, Science.

[43]  P. Crino,et al.  Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia , 2001, Neurology.

[44]  G. Sperk,et al.  Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Bredt,et al.  PDZ Proteins Organize Synaptic Signaling Pathways , 1998, Cell.

[46]  David Machin,et al.  Sample Size Tables for Clinical Studies , 1997 .

[47]  M. Baudry,et al.  Regional distribution and time-course of calpain activation following kainate-induced seizure activity in adult rat brain , 1996, Brain Research.

[48]  D. Fujikawa.  The temporal evolution of neuronal damage from pilocarpine-induced status epilepticus , 1996, Brain Research.

[49]  D. Bredt,et al.  Interaction of Nitric Oxide Synthase with the Postsynaptic Density Protein PSD-95 and α1-Syntrophin Mediated by PDZ Domains , 1996, Cell.

[50]  D. Fujikawa.  Neuroprotective Effect of Ketamine Administered After Status Epilepticus Onset , 1995, Epilepsia.

[51]  D. Fujikawa,et al.  The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage , 1994, Epilepsy Research.

[52]  T. Dawson,et al.  Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53]  P. Barone,et al.  Expression of c‐fos protein in the experimental epilepsy induced by pilocarpine , 1993, Synapse.

[54]  J. Olney,et al.  NMDA antagonist neurotoxicity: mechanism and prevention. , 1991, Science.

[55]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[56]  E M Glaser,et al.  Neuron imaging with Neurolucida--a PC-based system for image combining microscopy. , 1990, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[57]  R. Fariello,et al.  Potentiation of kainic acid epileptogenicity and sparing from neuronal damage by an NMDA receptor antagonist , 1989, Epilepsy Research.

[58]  R. Siman,et al.  Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[59]  G. Lynch,et al.  Stimulation of NMDA receptors induces proteolysis of spectrin in hippocampus , 1988, Brain Research.

[60]  T. Curran,et al.  Expression of c-fos protein in brain: metabolic mapping at the cellular level. , 1988, Science.

[61]  R. C. Collins,et al.  The functional anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine seizures , 1987, Neuroscience.

[62]  T. Curran,et al.  Mapping patterns of c-fos expression in the central nervous system after seizure. , 1987, Science.

[63]  E. Cavalheiro,et al.  Seizures produced by pilocarpine: Neuropathological sequelae and activity of glutamate decarboxylase in the rat forebrain , 1986, Brain Research.

[64]  M. Tymianski,et al.  Neuroprotectants Targeting NMDA Receptor Signaling , 2014 .

[65]  L. Liaudet,et al.  Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.

[66]  G. Avanzini,et al.  Prenatal methylazoxymethanol treatment in rats produces brain abnormalities with morphological similarities to human developmental brain dysgeneses. , 1999, Journal of neuropathology and experimental neurology.

[67]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .